Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc Analyst and Investor Event on Plozasiran and Zodasiran (Virtual) Transcript

Nov 13, 2023 / 09:30PM GMT
Operator

Good afternoon, and welcome to the Arrowhead Pharmaceuticals' Virtual Analyst and Investor Event. (Operator Instructions). As a reminder, this call is being recorded and the replay will be available on the Arrowhead website following the conclusion of the event.

I'd now like to turn the call over to Vince Anzalone of Arrowhead Pharmaceuticals. Please go ahead, Vince.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Thank you, Tara, and thanks, everybody, for joining us today. We've got a lot to cover. We presented data at AHA on 3 of the studies for 2 of our cardiometabolic programs for plozasiran, formerly known as ARO-APOC3, and zodasiran, formerly ARO-ANG3.

So before we start, I just want to let you know that we will be making forward-looking statements, so please refer to our SEC filings for risks.

And we've got a really great panel today -- sorry, let me get to that slide. Sorry. We have Dr. Daniel Gaudet from the University of Montreal, Børge Nordestgaard from University of Copenhagen and Dr. Steven

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot